Tymlos (Abaloparatide) Compounding Legal Status: What Women Need to Know

The Short Answer on Compounding: Tymlos Cannot Legally Be Compounded

Compounded abaloparatide is not legally available in the United States under current federal law. The FDA has not placed abaloparatide on the Section 503A bulk drug substances list or the Section 503B bulk drug substances list, which are the two pathways through which a compounding pharmacy can legally prepare copies of an approved drug. Any pharmacy or telehealth provider selling "compounded abaloparatide" is operating outside federal law.

This matters because unregulated compounded injectables carry real risks: sterility failures, incorrect concentration, and absence of the safety monitoring that accompanied the brand product through trials.

Why Compounding Became a Hot Topic for Bone Drugs

The surge of interest in compounded GLP-1 drugs over 2023 and 2024 created a broader consumer expectation that compounded versions of almost any injectable are available and legal. They are not. Unlike semaglutide and tirzepatide, which were placed on the FDA shortage list and therefore temporarily allowed to be compounded, abaloparatide has never appeared on the FDA drug shortage database in a manner that triggers compounding permissions. The brand Tymlos remains commercially available from Radius Health.

What 503A and 503B Actually Mean for You

Under the Drug Quality and Security Act of 2013, two pathways govern compounding:

• 503A covers traditional pharmacy compounding for individual patient prescriptions. A drug can be compounded under 503A only if the active ingredient appears on the FDA's approved bulk substances list, or if the drug is not commercially available.
• 503B covers outsourcing facilities that produce larger batches. The same basic restrictions apply.

Abaloparatide meets neither condition today. It is commercially available, and its active ingredient has not been nominated and approved for either list.

What Is Tymlos and What Is It Approved For?

Tymlos is a synthetic analog of human parathyroid hormone-related protein (PTHrP), specifically the 1-34 residue segment. It was approved by the FDA on April 28, 2017 for the treatment of osteoporosis in postmenopausal women at high risk of fracture. "High risk" in the label means women with a history of osteoporotic fracture, multiple fracture risk factors, or women who have failed or are intolerant of other available osteoporosis therapies.

The approval was anchored on the ACTIVE trial, a phase 3 randomized controlled trial published in JAMA in 2016. ACTIVE enrolled 2,463 postmenopausal women and compared abaloparatide 80 mcg daily, teriparatide 20 mcg daily, and placebo over 18 months. The primary endpoint was new vertebral fracture.

ACTIVE Trial Results You Should Know

• Abaloparatide reduced new vertebral fractures by 86% relative to placebo (0.58% vs 4.22%; absolute risk reduction 3.64%).
• Non-vertebral fracture risk was reduced by 43% vs placebo in the abaloparatide group.
• Abaloparatide showed a statistically significant advantage over teriparatide in reducing non-vertebral fractures at 18 months, a finding that has not yet been replicated in a longer trial powered specifically for that endpoint.
• Lumbar spine BMD increased by a mean of 9.2% from baseline in the abaloparatide group at 18 months.

The ACTIVE-Extend study followed participants who completed ACTIVE and transitioned to alendronate, confirming that the BMD gains achieved during abaloparatide treatment were maintained for at least 24 additional months with antiresorptive therapy.

How It Works Differently From Teriparatide

Both abaloparatide and teriparatide are anabolic agents, meaning they build bone rather than simply slowing bone loss. The mechanistic difference is receptor selectivity. Abaloparatide preferentially binds the RG conformation of the PTH1 receptor, which produces a shorter-duration, more bone-selective anabolic signal. In practical terms, this translates to lower rates of hypercalcemia: 3.4% in the abaloparatide group vs 6.4% in the teriparatide group in ACTIVE, a difference that matters for women with a history of kidney stones or who are on calcium supplementation.

The Tymlos Label: Key Points Women and Prescribers Must Know

The FDA-approved Tymlos prescribing information contains several provisions that directly affect how this drug is used in women across life stages.

Boxed Warning: Osteosarcoma

The label carries a black box warning for osteosarcoma based on rat studies showing dose-dependent osteosarcoma incidence at exposures 4 to 28 times the human clinical exposure. No causal association between abaloparatide and osteosarcoma has been established in humans to date, but this is the reason the drug is:

1. Contraindicated in patients at increased baseline risk of osteosarcoma (Paget disease of bone, prior radiation to the skeleton, bone metastases, metabolic bone diseases other than osteoporosis, prior skeletal malignancy).
2. Limited to a 2-year cumulative lifetime maximum across all PTH analogs combined (abaloparatide and teriparatide together).

If you have already received a full course of teriparatide, you cannot receive a full 2-year course of abaloparatide in addition. Your lifetime anabolic window has been used.

Orthostatic Hypotension

Abaloparatide can cause orthostatic hypotension, typically within 4 hours of injection. The Tymlos prescribing information recommends that patients administer the injection in a sitting or lying position and remain seated or supine for a few minutes afterward if they feel lightheaded. This is particularly relevant for women in early postmenopause who may already experience vasomotor instability.

Hypercalcemia and Hypercalciuria

Women on calcium supplements, vitamin D, or thiazide diuretics should have their calcium levels checked within the first months of therapy. The label does not require routine serum calcium monitoring beyond standard of care, but the FDA-reviewed safety data document that urinary calcium excretion increases, which raises kidney stone risk in susceptible individuals.

Dosing

The approved dose is 80 mcg once daily by subcutaneous injection into the periumbilical abdomen, delivered via a prefilled multi-dose pen. The pen delivers 30 doses. Women should rotate injection sites within the periumbilical area and avoid areas that are bruised, tender, or scarred.

A practical framework for deciding when Tymlos is the right anabolic agent vs alternatives:

| Clinical situation | Preferred anabolic agent | Rationale | |---|---|---| | High fracture risk, no prior PTH analog, history of kidney stones | Abaloparatide | Lower hypercalciuria than teriparatide | | High fracture risk, no prior PTH analog, no kidney stone history | Either; cost and access decide | Comparable vertebral fracture efficacy | | Prior teriparatide course (2 years) | Neither PTH analog (lifetime limit reached) | Romosozumab or antiresorptive therapy | | Premenopausal woman, very low BMD, not planning pregnancy | Discuss with specialist; limited label data | Neither approved for premenopausal women | | Active pregnancy or breastfeeding | Neither; see below | Contraindicated |

Pregnancy, Lactation, and Contraception: Required Reading

Tymlos is contraindicated in pregnancy. This is not a relative caution. This section applies to any woman of reproductive age who may receive Tymlos off-label, and it is mandatory reading before the pen is dispensed.

Pregnancy Category and Human Data

Abaloparatide does not carry an older letter-category designation because it was approved after the FDA replaced the A/B/C/D/X system with the Pregnancy and Lactation Labeling Rule (PLLR) in 2015. Under the PLLR format, the Tymlos label states:

• Animal reproduction studies in rats showed fetal skeletal abnormalities at subcutaneous doses producing exposures approximately 16 times the human clinical exposure.
• There are no adequate and well-controlled studies in pregnant women. Human data are essentially absent.
• Abaloparatide should not be used during pregnancy.

Any woman of childbearing potential who is prescribed Tymlos off-label (for example, a premenopausal woman with glucocorticoid-induced osteoporosis or a woman in perimenopause with very low T-score) must use effective contraception for the duration of treatment. The drug has no reversal agent, and because it is a 30-dose pen used daily, a pregnancy can occur before a woman realizes she conceived.

Lactation

The prescribing information does not include human lactation data. It is unknown whether abaloparatide or its metabolites are present in human milk. The developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need, but given the absence of safety data in infants and the availability of alternative treatments postpartum, most clinicians and the label itself advise against use during breastfeeding. Abaloparatide is not a drug that a postpartum or lactating woman should be taking under standard clinical guidance.

Postpartum Bone Loss Context

Postpartum and lactation-associated osteoporosis is a real, under-recognized condition. Women who experience severe bone loss during pregnancy or lactation may have T-scores that appear to warrant aggressive treatment. However, the appropriate management of lactation-associated osteoporosis typically involves stopping lactation, correcting calcium and vitamin D deficiency, and monitoring BMD recovery, which is often substantial. PTH analogs including abaloparatide have been used off-label in severe cases after weaning, but this decision belongs in the hands of a specialist, not a compounding pharmacy.

Life-Stage Guide: Who This Drug Is and Is Not Right For

Tymlos was studied and approved exclusively in postmenopausal women. The ACTIVE trial enrolled women with a mean age of 69 years. What this means for women at other life stages requires careful extrapolation.

Postmenopause (Primary Indicated Population)

Postmenopausal women with a FRAX 10-year major osteoporotic fracture probability of 20% or more, or a hip fracture probability of 3% or more, are candidates for pharmacologic therapy per NOF/ASBMR guidelines. Among those, women at very high fracture risk (T-score below -3.0, prior hip or vertebral fracture, or fracture on antiresorptive therapy) are the group where an anabolic agent like abaloparatide makes the clearest clinical sense. After completing a 2-year abaloparatide course, sequential antiresorptive therapy with a bisphosphonate or denosumab is required to preserve gains, per Endocrine Society guidance.

Perimenopause

Perimenopause involves rapid estrogen decline and accelerated bone loss, with some women losing up to 10% of bone mass in the first 5 years after menopause. Women in perimenopause with a fragility fracture or very low T-score may be considered for anabolic therapy, but abaloparatide is not labeled for this group. Menopausal hormone therapy (MHT) remains the first-line option for perimenopausal bone protection in most guidelines.

Reproductive Years and TTC

Women in their reproductive years do not typically have osteoporosis severe enough to warrant PTH analog therapy. If a premenopausal woman has glucocorticoid-induced osteoporosis or a genetic bone disease causing very low BMD, abaloparatide could theoretically be considered after other options have failed, but she must not be pregnant, must not be breastfeeding, and must use reliable contraception throughout treatment. Reliable contraception in this context means a method with a Pearl Index below 1 (IUD, implant, combined hormonal contraception). Barrier methods alone are not adequate given the fetal skeletal harm seen in animal studies.

Trying to Conceive

Do not use Tymlos if you are trying to conceive. Discontinue at least one full menstrual cycle before attempting pregnancy, though the absence of human safety data means even this interval is extrapolated rather than evidence-based.

Tymlos Safety Profile: What the Post-Market Data Add

The ACTIVE trial ran for 18 months and was powered for fracture endpoints, not for rare adverse events. Post-market safety data from the FDA Adverse Event Reporting System (FAERS) and the FDA Sentinel system add real-world context.

Common Adverse Effects (Seen in More Than 2% of ACTIVE Participants)

• Hypercalciuria: 11.3% (abaloparatide) vs 9.3% (placebo)
• Dizziness: 10.3% vs 6.0%
• Nausea: 8.5% vs 5.5%
• Headache: 8.0% vs 6.0%
• Palpitations: 6.9% vs 3.3%
• Injection-site reactions: erythema, pain, bruising at the periumbilical injection site are reported by approximately 58% of users and are generally mild and self-limiting

Palpitations: A Sex-Specific Note

The palpitation signal in ACTIVE (6.9% abaloparatide vs 3.3% placebo) is clinically meaningful for women who already experience palpitations during perimenopause or as a vasomotor symptom. Postmenopausal women have a higher baseline rate of palpitations than premenopausal women, partly because estrogen withdrawal affects cardiac autonomic tone. A woman who starts abaloparatide and develops new palpitations should report them to her clinician, who will need to distinguish drug effect from an underlying arrhythmia.

Osteosarcoma Surveillance

The FDA required Radius Health to conduct a 10-year osteosarcoma surveillance study as a post-marketing commitment. As of the most recent publicly available data, no causal link between abaloparatide and human osteosarcoma has been confirmed, but this study is ongoing and the black box warning remains in place. Women should not dismiss the warning, but they should also understand that the absolute baseline risk of osteosarcoma in the postmenopausal population is extremely low.

Evidence Gap Transparency

The ACTIVE trial enrolled only postmenopausal women. There are no randomized trial data on abaloparatide in:

• Premenopausal women
• Women with PCOS-related bone disease
• Women with glucocorticoid-induced osteoporosis (though studies exist for teriparatide in this group)
• Women with aromatase inhibitor-induced bone loss (breast cancer treatment)
• Black and Hispanic women in proportions matching U.S. Population demographics (ACTIVE was predominantly white)

Any use in these groups is extrapolated from the ACTIVE data and from pharmacologic principles. This is an honest limitation of the evidence base.

Abaloparatide and Female-Relevant Conditions

PCOS and Bone Health

Women with PCOS have complex hormonal profiles that may affect bone density. Some studies suggest that women with PCOS have normal or slightly elevated BMD despite metabolic dysfunction, possibly because of higher androgen levels and higher body weight acting as a mechanical load. This means most women with PCOS are not candidates for abaloparatide. The exception is a woman with PCOS who has also undergone premature ovarian insufficiency or prolonged amenorrhea with very low estrogen, leading to bone loss.

Aromatase Inhibitor-Induced Bone Loss

Women receiving aromatase inhibitors (AIs) for hormone receptor-positive breast cancer can lose 2 to 3% of bone density per year during AI therapy. Standard management involves bisphosphonates or denosumab. Abaloparatide is not approved for this indication, and given the absence of data and the theoretical concern about any bone-active agent in a setting of active oncology treatment, AI-induced bone loss management should remain within the oncology team.

Glucocorticoid-Induced Osteoporosis

Women with autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) who require long-term glucocorticoid therapy represent a high-risk group for bone loss at a younger age. The ACR 2022 guidelines for glucocorticoid-induced osteoporosis recommend teriparatide as the preferred anabolic agent in very high-risk patients. Abaloparatide has not been studied in this population in a dedicated trial, though its mechanism is similar enough that some specialist centers use it when teriparatide is not tolerated or available.

Frequently Asked Questions